Source comparison
Dosing Protocols — Research-Grade vs FDA-Approved Formulations
The FDA-approved formulation of Melanotan-1 (Scenesse) is delivered as a biodegradable subcutaneous implant containing 16mg afamelanotide, designed to release the peptide gradually over 60 days. This is the only legally marketed form of MT-1 for medical use, a
This comparison does not assign a generated winner or score.
- The FDA-approved formulation of Melanotan-1 (Scenesse) is delivered as a biodegradable subcutaneous implant containing 16mg afamelanotide, designed to release the peptide gradually over 60 days. This is the only legally marketed form of MT-1 for medical use, approved specifically for erythropoietic protoporphyria (EPP). A rare photosensitivity disorder where patients experience severe phototoxic reactions to visible light. The implant is placed subcutaneously in the suprainguinal region (above the hip) under sterile conditions by a trained clinician.
- Research-grade Melanotan-1, available through suppliers like Real Peptides, is provided as lyophilized powder in vials typically containing 10mg per vial. Unlike the implant, research formulations require reconstitution with bacteriostatic water and are administered via subcutaneous injection. Experimental dosing protocols documented in early-phase trials used 0.16mg/kg loading doses followed by 0.08mg/kg maintenance doses administered 2–3 times weekly, though these regimens were designed for photoprotection research rather than cosmetic tanning.
- Critical distinction: research peptides are not FDA-approved for human therapeutic use and are sold exclusively for laboratory research under the Federal Food, Drug, and Cosmetic Act. Any dosing information provided here is sourced from published clinical trial data and does not constitute medical advice or endorsement for off-label use. Peptide stability after reconstitution is limited to 28 days when refrigerated at 2–8°C. Exceeding this window risks protein degradation and loss of bioactivity.